Abpro Holdings, Inc.

Abpro Holdings, Inc., trading on Nasdaq under the ticker ABP, is a clinical-stage biopharmaceutical company that entered the public markets through a SPAC business combination, operating in the healthcare and biotechnology sector. The company filed an 8-K with the Securities and Exchange Commission on April 8, 2025, under accession number 0001213900-25-029934, reflecting a material disclosure event following its public listing. Abpro focuses on the development of bispecific antibody therapeutics, positioning itself within an oncology-focused pipeline. The filing reflects the company's continued reporting obligations as a publicly traded SPAC-derived entity. For complete filing details, sponsor history, and SPAC transaction analytics on ABP and hundreds of other names, sign up for full data access at SpacDesk.